This eight-month study is evaluating the efficacy of two doses of this new medication compared to placebo in lowering pain intensity in patients with PHN.
Major Inclusion/Exclusion Criteria:
- Ages 18-80
- Persistent PHN pain for a minimum of 9 months following a the onset of a herpes zoster skin rash (shingles)
- Must be on only one chronic pain drug, and must be willing to stay on that drug maintaining that stable dose for the duration of the study
- Must not have any other neuropathic pain